gemcitabine has been researched along with cp 4126 in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Galmarini, CM; Myhren, F; Sandvold, ML | 1 |
| Adema, AD; Balzarini, J; Bergman, AM; Bruheim, S; Fichtner, I; Fodstad, O; Hendriks, HR; Myhren, F; Noordhuis, P; Peters, GJ; Sandvold, ML | 1 |
| Adema, AD; Honeywell, RJ; Losekoot, N; Myhren, F; Peters, GJ; Sandvold, ML; Smid, K; Verheul, HM | 1 |
| Awada, A; Bergeland, T; Hals, PA; Hendlisz, A; Rasch, W; Schellens, JH; Stuurman, FE; Voest, EE; Witteveen, PO | 1 |
| Allen, A; Andersson, R; Bassi, C; Boeck, S; Bondar, V; Bondarenko, I; Davidenko, I; Dicker, A; Evans, TR; Garin, A; Hahn, H; Heinemann, V; Ikdahl, T; Isaacson, J; Kaur, P; Mann, E; Ormanns, S; Picozzi, V; Poplin, E; Raponi, M; Rolfe, L; Voong, C; Wasan, H | 1 |
2 trial(s) available for gemcitabine and cp 4126
| Article | Year |
|---|---|
Phase I study of oral CP-4126, a gemcitabine derivative, in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Demography; Deoxycytidine; Female; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Staging; Neoplasms | 2013 |
Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Carcinoma, Pancreatic Ductal; Deoxycytidine; Equilibrative Nucleoside Transporter 1; Female; Gemcitabine; Humans; Immunohistochemistry; In Vitro Techniques; Middle Aged; Neoplasm Metastasis; Neutropenia; Pancreatic Neoplasms; Prognosis; Prospective Studies; Survival Analysis; Treatment Outcome | 2013 |
3 other study(ies) available for gemcitabine and cp 4126
| Article | Year |
|---|---|
CP-4055 and CP-4126 are active in ara-C and gemcitabine-resistant lymphoma cell lines.
Topics: Cell Line, Tumor; Cell Membrane; Cytarabine; Deoxycytidine; Drug Resistance, Neoplasm; Gemcitabine; Humans; Lymphoma | 2009 |
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Cell Death; Cell Line, Tumor; Cell Proliferation; Cytidine Deaminase; Deoxycytidine; Disease Models, Animal; Dogs; Fatty Acids; Gemcitabine; Humans; Mice; Nucleoside Deaminases; Treatment Outcome; Xenograft Model Antitumor Assays | 2011 |
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126.
Topics: Antineoplastic Agents; Cell Line; Cytarabine; Deoxycytidine; Deoxycytidine Kinase; Dipyridamole; Drug Resistance, Neoplasm; Gemcitabine; Humans; Leukemia; Nucleoside Transport Proteins; Nucleotidases | 2012 |